Nobutaka Horie

Nobutaka Horie

Auto-generated profile, based on publicly available information

Nobutaka Horie

Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2014 in Stroke
Verified
Journal Article
Closed access
SMSusumu Miyamoto
Susumu Miyamoto
TYTakashi Yoshimoto
Takashi Yoshimoto
NHNobuo Hashimoto
Nobuo Hashimoto
YOYasushi Okada
Yasushi Okada
ITIchiro Tsuji
Ichiro Tsuji
YTYukiko Tsutsumi
Yukiko Tsutsumi
Background and Purpose—: About one half of those who develop adult-onset moyamoya disease experience intracranial hemorrhage. Despite the extremely high frequency of rebleeding attacks and poor prognosis, measures to prevent rebleeding have not been established. The purpose of this study is to determine whether extracranial–intracranial bypass can reduce incidence of rebleeding and improve patient prognosis. Methods—: This study was a multicentered, prospective, randomized, controlled trial conducted by 22 institutes in Japan. Adult patients with moyamoya disease who had experienced intracranial hemorrhage within the preceding year were given either conservative care or bilateral extracranial–intracranial direct bypass and were observed for 5 years. Primary and secondary end points were defined as all adverse events and rebleeding attacks, respectively. Results—: Eighty patients were enrolled (surgical, 42; nonsurgical, 38). Adverse events causing significant morbidity were observed in 6 patients in the surgical group (14.3%) and 13 patients in the nonsurgical group (34.2%). Kaplan–Meier survival analysis revealed significant differences between the 2 groups (3.2%/y versus 8.2%/y; P =0.048). The hazard ratio of the surgical group calculated by Cox regression analysis was 0.391 (95% confidence interval, 0.148–1.029). Rebleeding attacks were observed in 5 patients in the surgical group (11.9%) and 12 in the nonsurgical group (31.6%), significantly different in the Kaplan–Meier survival analysis (2.7%/y versus 7.6%/y; P =0.042). The hazard ratio of the surgical group was 0.355 (95% confidence interval, 0.125–1.009). Conclusions—: Although statistically marginal, Kaplan–Meier analysis revealed the significant difference between surgical and nonsurgical group, suggesting the preventive effect of direct bypass against rebleeding. Clinical Trial Registration—: URL: http://www.umin.ac.jp/ctr/index.htm . Unique identifier: C000000166.

24 May 2011 in Brain
Verified
Journal Article
Open access
PDF file
RARobert H. Andres
Robert H. Andres
NHNobutaka Horie
Nobutaka Horie
WSWilliam Slikker
William Slikker
HKHadar Keren-Gill
Hadar Keren-Gill
KZKe Zhan
Ke Zhan
GSGary K. Steinberg
Gary K. Steinberg
Stem cell transplantation promises new hope for the treatment of stroke although significant questions remain about how the grafted cells elicit their effects. One hypothesis is that transplanted stem cells enhance endogenous repair mechanisms activated after cerebral ischaemia. Recognizing that bilateral reorganization of surviving circuits is associated with recovery after stroke, we investigated the ability of transplanted human neural progenitor cells to enhance this structural plasticity. Our results show the first evidence that human neural progenitor cell treatment can significantly increase dendritic plasticity in both the ipsi- and contralesional cortex and this coincides with stem cell-induced functional recovery. Moreover, stem cell-grafted rats demonstrated increased corticocortical, corticostriatal, corticothalamic and corticospinal axonal rewiring from the contralesional side; with the transcallosal and corticospinal axonal sprouting correlating with functional recovery. Furthermore, we demonstrate that axonal transport, which is critical for both proper axonal function and axonal sprouting, is inhibited by stroke and that this is rescued by the stem cell treatment, thus identifying another novel potential mechanism of action of transplanted cells. Finally, we established in vitro co-culture assays in which these stem cells mimicked the effects observed in vivo. Through immunodepletion studies, we identified vascular endothelial growth factor, thrombospondins 1 and 2, and slit as mediators partially responsible for stem cell-induced effects on dendritic sprouting, axonal plasticity and axonal transport in vitro. Thus, we postulate that human neural progenitor cells aid recovery after stroke through secretion of factors that enhance brain repair and plasticity.

14 January 2011 in Stem Cells
Verified
Journal Article
Open access
PDF file
NHNobutaka Horie
Nobutaka Horie
MPMarta P. Pereira
Marta P. Pereira
KNKuniyasu Niizuma
Kuniyasu Niizuma
GSGuohua Sun
Guohua Sun
HKHadar Keren-Gill
Hadar Keren-Gill
GSGary K. Steinberg
Gary K. Steinberg
Cell transplantation offers a novel therapeutic strategy for stroke; however, how transplanted cells function in vivo is poorly understood. We show for the first time that after subacute transplantation into the ischemic brain of human central nervous system stem cells grown as neurospheres (hCNS-SCns), the stem cell-secreted factor, human vascular endothelial growth factor (hVEGF), is necessary for cell-induced functional recovery. We correlate this functional recovery to hVEGF-induced effects on the host brain including multiple facets of vascular repair and its unexpected suppression of the inflammatory response. We found that transplanted hCNS-SCns affected multiple parameters in the brain with different kinetics: early improvement in blood-brain barrier integrity and suppression of inflammation was followed by a delayed spatiotemporal regulated increase in neovascularization. These events coincided with a bimodal pattern of functional recovery, with, an early recovery independent of neovascularization, and a delayed hVEGF-dependent recovery coincident with neovascularization. Therefore, cell transplantation therapy offers an exciting multimodal strategy for brain repair in stroke and potentially other disorders with a vascular or inflammatory component.

29 March 2007 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
TMTakahiro Moriya
Takahiro Moriya
NHNobutaka Horie
Nobutaka Horie
MMMasato Mitome
Masato Mitome
KSKazuyuki Shinohara
Kazuyuki Shinohara

1 March 2011 in Journal of Neuroscience Methods
Verified
Journal Article
Closed access
AEAngelo Encarnacion
Angelo Encarnacion
NHNobutaka Horie
Nobutaka Horie
HKHadar Keren-Gill
Hadar Keren-Gill
TBTonya M. Bliss
Tonya M. Bliss
GSGary K. Steinberg
Gary K. Steinberg
DBDenise Briggs
Denise Briggs

1 January 2016 in Stroke
Verified
Journal Article
Closed access
JTJun C. Takahashi
Jun C. Takahashi
TFTakeshi Funaki
Takeshi Funaki
KHKiyohiro Houkin
Kiyohiro Houkin
TITooru Inoue
Tooru Inoue
KOKuniaki Ogasawara
Kuniaki Ogasawara
YTYukiko Tsutsumi
Yukiko Tsutsumi
Background and Purpose—: The primary results of the Japan Adult Moyamoya Trial revealed the statistically marginal superiority of bypass surgery over medical treatment alone in preventing rebleeding in moyamoya disease. The purpose of this analysis is to test the prespecified subgroup hypothesis that the natural course and surgical effects vary depending on the hemorrhagic site at onset. Methods—: The hemorrhagic site, classified as either anterior or posterior, was the only stratifying variable for randomization. Statistical analyses were focused on the assessment of effect modification according to the hemorrhagic site and were based on tests of interaction. Results—: Of 42 surgically treated patients, 24 were classified as anterior hemorrhage and 18 as posterior hemorrhage; of 38 medically treated patients, 21 were classified as anterior and 17 as posterior. The hazard ratio of the primary end points (all adverse events) for the surgical group relative to the nonsurgical group was 0.07 (95% confidence interval, 0.01–0.55) for the posterior group, as compared with 1.62 (95% confidence interval, 0.39–6.79) for the anterior group ( P =0.013 for interaction). Analysis within the nonsurgical group revealed that the incidence of the primary end point was significantly higher in the posterior group than in the anterior group (17.1% per year versus 3.0% per year; hazard ratio, 5.83; 95% confidence interval, 1.60–21.27). Conclusions—: Careful interpretation of the results suggests that patients with posterior hemorrhage are at higher risk of rebleeding and accrue greater benefit from surgery, subject to verification in further studies. Clinical Trial Registration—: URL: http://www.umin.ac.jp/ctr/index.htm . Unique identifier: C000000166.